Michael J Duffy

List of Publications by Year
in descending order

133 papers	15,278 citations	16451 64 h-index	17592 121 g-index
135 all docs	135 docs citations	135 times ranked	18709 citing authors

#	Article	IF	Citations
1	Targeting p53 for the treatment of cancer. Seminars in Cancer Biology, 2022, 79, 58-67.	9.6	177
2	Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer. Journal of Personalized Medicine, 2022, 12, 99.	2.5	16
3	OUP accepted manuscript. Clinical Chemistry, 2022, , .	3.2	5
4	Circulating cancer biomarkers: current status and future prospects. , 2022, , 409-443.		0
5	Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells. , 2022, 39, .		10
6	Drugging â€œundruggableâ€•genes for cancer treatment: Are we making progress?. International Journal of Cancer, 2021, 148, 8-17.	5.1	63
7	The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells. Investigational New Drugs, 2021, 39, 587-594.	2.6	10
8	Bringing Onco-Innovation to Europeâ€™s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. Cancers, 2021, 13, 583.	3.7	13
9	MYC as a target for cancer treatment. Cancer Treatment Reviews, 2021, 94, 102154.	7.7	170
10	Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1353-1361.	2.3	25
11	COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells. Breast Cancer Research and Treatment, 2020, 179, 47-56.	2.5	51
12	Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clinical Chemistry and Laboratory Medicine, 2020, 58, 326-339.	2.3	123
13	Bringing Greater Accuracy to Europeâ€™s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. Biomedicine Hub, 2020, 5, 1-42.	1.2	15
14	Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A. Investigational New Drugs, 2020, 38, 1365-1372.	2.6	5
15	Circulating tumour DNA as a cancer biomarker. Annals of Clinical Biochemistry, 2019, 56, 42-48.	1.6	13
16	Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. Clinical Chemistry, 2019, 65, 1228-1238.	3.2	178
17	Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells. Cancers, 2019, 11, 548.	3.7	19
18	HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells. Cancers, 2019, 11, 197.	3.7	21

#	Article	IF	Citations
19	Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Research and Treatment, 2018, 170, 213-219.	2.5	144
20	Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. Cancer Letters, 2018, 414, 99-106.	7.2	48
21	Prognostic and predictive biomarkers in breast cancer: Past, present and future. Seminars in Cancer Biology, 2018, 52, 56-73.	9.6	284
22	An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer. Cancer Management and Research, 2018, Volume 10, 6879-6886.	1.9	6
23	The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells. Translational Oncology, 2018, 11, 1343-1349.	3.7	25
24	Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA. Tumor Biology, 2018, 40, 101042831877616.	1.8	50
25	Tissue and Blood Biomarkers in Lung Cancer: A Review. Advances in Clinical Chemistry, 2018, 86, 1-21.	3.7	85
26	Targeting mutant p53 with COTI-2: A new approach for the treatment of patients with triple-negative breast cancer?. Journal of Clinical Oncology, 2018, 36, e13121-e13121.	1.6	2
27	Vitamin D analogues: Potential use in cancer treatment. Critical Reviews in Oncology/Hematology, 2017, 112, 190-197.	4.4	72
28	Vitamin D receptor as a target for breast cancer therapy. Endocrine-Related Cancer, 2017, 24, 181-195.	3.1	40
29	Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). European Journal of Cancer, 2017, 75, 284-298.	2.8	363
30	Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy. Clinical Chemistry, 2017, 63, 804-806.	3.2	10
31	Mutant p53 as a target for cancer treatment. European Journal of Cancer, 2017, 83, 258-265.	2.8	287
32	Mutant p53: a novel target for the treatment of patients with tripleâ€negative breast cancer?. International Journal of Cancer, 2017, 140, 234-246.	5.1	79
33	Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells.. Journal of Clinical Oncology, 2017, 35, e14098-e14098.	1.6	3
34	Targeting mutant p53 with PK11007: A new approach for the treatment of patients with triple-negative breast cancer?. Journal of Clinical Oncology, 2017, 35, e14099-e14099.	1.6	4
35	Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. International Journal of Gynecological Cancer, 2016, 26, 43-51.	2.5	195
36	The ADAMs family of proteases as targets for the treatment of cancer. Cancer Biology and Therapy, 2016, 17, 870-880.	3.4	87

#	Article	IF	Citations
37	Validated biomarkers: The key to precision treatment in patients with breast cancer. Breast, 2016, 29, 192-201.	2.2	47
38	Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells. Endocrine-Related Cancer, 2016, 23, 323-334.	3.1	50
39	p53 in cancer: ready for therapeutic targeting?. Translational Cancer Research, 2016, 5, 627-631.	1.0	5
40	The vitamin D receptor as a target for the treatment of breast cancer: Studies with the low calcemic vitamin D analog, inecalcitol.. Journal of Clinical Oncology, 2016, 34, e12011-e12011.	1.6	0
41	Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Prelinical investigation with the anti-p53 drug, APR-246.. Journal of Clinical Oncology, 2016, 34, 1082-1082.	1.6	0
42	Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. British Journal of Cancer, 2015, 112, 1895-1903.	6.4	52
43	Biomarkers in Breast Cancer. Advances in Clinical Chemistry, 2015, 71, 1-23.	3.7	86
44	Personalized treatment for patients with colorectal cancer: role of biomarkers. Biomarkers in Medicine, 2015, 9, 337-347.	1.4	20
45	Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers. Clinical Chemistry, 2015, 61, 809-820.	3.2	120
46	ADAM10: a new player in breast cancer progression?. British Journal of Cancer, 2015, 113, 945-951.	6.4	61
47	Use of Biomarkers in Screening for Cancer. Advances in Experimental Medicine and Biology, 2015, 867, 27-39.	1.6	45
48	Neratinib to inhibit the growth of triple-negative breast cancer cells.. Journal of Clinical Oncology, 2015, 33, 1099-1099.	1.6	7
49	The vitamin D receptor: A therapeutic target for the treatment of breast cancer?. Journal of Clinical Oncology, 2015, 33, 534-534.	1.6	3
50	Enzalutamide: A new hormonal treatment for triple-negative breast cancer?. Journal of Clinical Oncology, 2015, 33, 1071-1071.	1.6	0
51	ADAM10 and ADAM17: New Players in Trastuzumab Resistance. Oncotarget, 2014, 5, 10963-10964.	1.8	11
52	cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?. Expert Opinion on Therapeutic Targets, 2014, 18, 999-1009.	3.4	24
53	PSA in Screening for Prostate Cancer. Advances in Clinical Chemistry, 2014, , 1-23.	3.7	26
54	Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. International Journal of Cancer, 2014, 134, 2513-2522.	5.1	288

#	Article	IF	Citations
55	Precision treatment for cancer: Role of prognostic and predictive markers. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 30-45.	6.1	25
56	Investigation of molecular alterations of <scp>AKT</scp>â€3 in tripleâ€negative breast cancer. Histopathology, 2014, 64, 660-670.	2.9	20
57	<scp>ADAM</scp>8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Molecular Medicine, 2014, 6, 278-294.	6.9	88
58	p53 as a target for the treatment of cancer. Cancer Treatment Reviews, 2014, 40, 1153-1160.	7.7	187
59	uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Research, 2014, 16, 428.	5.0	201
60	Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers. Medical Principles and Practice, 2013, 22, 4-11.	2.4	203
61	The war on cancer: are we winning?. Tumor Biology, 2013, 34, 1275-1284.	1.8	42
62	Design of Tumor Biomarkerâ€"Monitoring Trials: A Proposal by the European Group on Tumor Markers. Clinical Chemistry, 2013, 59, 52-59.	3.2	37
63	Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer. Clinical Chemistry, 2013, 59, 1447-1456.	3.2	44
64	Exploring the Glycosylation of Serum CA125. International Journal of Molecular Sciences, 2013, 14, 15636-15654.	4.1	67
65	Met and HGF inhibition in triple-negative breast cancer cell lines.. Journal of Clinical Oncology, 2013, 31, 1066-1066.	1.6	1
66	Monitoring response to therapy in patients with cancer: is circulating DNA the answer?. Annals of Translational Medicine, 2013, 1, 24.	1.7	2
67	Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Research and Treatment, 2012, 136, 717-727.	2.5	35
68	The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERÎ±, and is an independent prognostic factor in node-negative breast cancer. Oncogene, 2012, 31, 3483-3494.	5.9	10
69	Targeted therapy for tripleâ€negative breast cancer: Where are we?. International Journal of Cancer, 2012, 131, 2471-2477.	5.1	76
70	Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Annals of Oncology, 2012, 23, 1788-1795.	1.2	112
71	Abstract 1845: ADAM10: A new player in breast cancer progression. , 2012, , .		1
72	Use of Tumor Markers in the Detection and Management of Patients with Colorectal Cancer. , 2012, , 315-329.		0

#	Article	IF	Citations
73	Use of molecular markers for predicting therapy response in cancer patients. Cancer Treatment Reviews, 2011, 37, 151-159.	7.7	94
74	The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory. Annals of Clinical Biochemistry, 2011, 48, 295-299.	1.6	18
75	Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?. Annals of Clinical Biochemistry, 2011, 48, 310-316.	1.6	17
76	The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?. Clinical Proteomics, 2011, 8, 9.	2.1	164
77	Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. International Journal of Cancer, 2011, 128, 3-11.	5.1	83
78	Src: a potential target for the treatment of triple-negative breast cancer. Annals of Oncology, 2011, 22, 2234-2240.	1.2	117
79	Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer, 2010, 10, 639.	2.6	38
80	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. Clinical Chemistry, 2010, 56, e1-e48.	3.2	184
81	Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib. Molecular Cancer Therapeutics, 2010, 9, 1489-1502.	4.1	283
82	Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Annals of Oncology, 2010, 21, 441-447.	1.2	300
83	Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients. Glycobiology, 2010, 20, 1283-1288.	2.5	41
84	Prioritization of Candidate Protein Biomarkers from an In Vitro Model System of Breast Tumor Progression Toward Clinical Verification. Journal of Proteome Research, 2010, 9, 1450-1459.	3.7	7
85	CA 15-3: Uses and limitation as a biomarker for breast cancer. Clinica Chimica Acta, 2010, 411, 1869-1874.	1.1	270
86	Use of Biomarkers in Screening for Cancer. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2010, 21, 1-12.	0.7	5
87	Role of ADAMs in Cancer Formation and Progression. Clinical Cancer Research, 2009, 15, 1140-1144.	7.0	196
88	Survivin: A new target for anti-cancer therapy. Cancer Treatment Reviews, 2009, 35, 553-562.	7.7	346
89	The role of ADAMs in disease pathophysiology. Clinica Chimica Acta, 2009, 403, 31-36.	1.1	56
90	Cancer invasion and metastasis: changing views. Journal of Pathology, 2008, 214, 283-293.	4.5	253

#	Article	IF	Citations
91	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clinical Chemistry, 2008, 54, e11-e79.	3.2	539
92	A Personalized Approach to Cancer Treatment: How Biomarkers Can Help. Clinical Chemistry, 2008, 54, 1770-1779.	3.2	136
93	Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Research, 2008, 10, R89.	5.0	113
94	ADAM-17 predicts adverse outcome in patients with breast cancer. Annals of Oncology, 2008, 19, 1075-1081.	1.2	75
95	Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer. Clinical Cancer Research, 2008, 14, 2681-2689.	7.0	83
96	Use of a Panel of Novel Genes for Differentiating Breast Cancer from Non-Breast Tissues. Tumor Biology, 2007, 28, 312-317.	1.8	6
97	ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression. Clinical Cancer Research, 2007, 13, 2335-2343.	7.0	108
98	Role of tumor markers in patients with solid cancers: A critical review. European Journal of Internal Medicine, 2007, 18, 175-184.	2.2	144
99	Survivin: A promising tumor biomarker. Cancer Letters, 2007, 249, 49-60.	7.2	229
100	CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. International Journal of Cancer, 2007, 120, 1434-1443.	5.1	98
101	Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. Cancer Genomics and Proteomics, 2007, 4, 121-34.	2.0	17
102	Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?. Clinical Chemistry, 2006, 52, 345-351.	3.2	367
103	Estrogen Receptors: Role in Breast Cancer. Critical Reviews in Clinical Laboratory Sciences, 2006, 43, 325-347.	6.1	82
104	CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer, 2006, 6, 220.	2.6	58
105	Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer. International Journal of Cancer, 2006, 120, 1087-1092.	5.1	13
106	CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance. Clinical Cancer Research, 2006, 12, 6421-6431.	7.0	123
107	Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of 2â€“10 ng/ml: Systematic Review and Meta-Analysis. European Urology, 2005, 48, 386-399.	1.9	222
108	Mammaglobin a in breast cancer: Existence of multiple molecular forms. International Journal of Cancer, 2005, 114, 623-627.	5.1	15

#	Article	IF	Citations
109	Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations. Tumor Biology, 2005, 26, 281-293.	1.8	287
110	Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. Expert Opinion on Biological Therapy, 2005, 5, 1069-1083.	3.1	46
111	DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2005, 3, 289-304.	0.3	10
112	Predictive Markers in Breast and Other Cancers: A Review. Clinical Chemistry, 2005, 51, 494-503.	3.2	143
113	Expression of the Breast Cancer Metastasis Suppressor Gene, BRMS1, in Human Breast Carcinoma: Lack of Correlation with Metastasis to Axillary Lymph Nodes. Tumor Biology, 2005, 26, 213-216.	1.8	31
114	Evidence for the clinical use of tumour markers. Annals of Clinical Biochemistry, 2004, 41, 370-377.	1.6	37
115	The Urokinase Plasminogen Activator System: Role in Malignancy. Current Pharmaceutical Design, 2004, 10, 39-49.	1.9	356
116	High Preoperative CA 15-3 Concentrations Predict Adverse Outcome in Node-Negative and Node-Positive Breast Cancer: Study of 600 Patients with Histologically Confirmed Breast Cancer. Clinical Chemistry, 2004, 50, 559-563.	3.2	82
117	Expression of ADAMâ€9 mRNA and protein in human breast cancer. International Journal of Cancer, 2003, 105, 754-761.	5.1	136
118	The ADAMs family of proteins: from basic studies to potential clinical applications. Thrombosis and Haemostasis, 2003, 89, 622-631.	3.4	71
119	The ADAMs family of proteins: from basic studies to potential clinical applications. Thrombosis and Haemostasis, 2003, 89, 622-31.	3.4	18
120	Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients. Journal of the National Cancer Institute, 2002, 94, 116-128.	6.3	548
121	Mammaglobin A: A Promising Marker for Breast Cancer. Clinical Chemistry, 2002, 48, 1362-1364.	3.2	49
122	Urokinase Plasminogen Activator and Its Inhibitor, PAI-1, as Prognostic Markers in Breast Cancer: From Pilot to Level 1 Evidence Studies. Clinical Chemistry, 2002, 48, 1194-1197.	3.2	208
123	Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clinical Chemistry, 2002, 48, 1194-7.	3.2	74
124	Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful?. Clinical Chemistry, 2001, 47, 624-630.	3.2	619
125	Biochemical markers in breast cancer: which ones are clinically useful?. Clinical Biochemistry, 2001, 34, 347-352.	1.9	77
126	Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Annals of Clinical Biochemistry, 2001, 38, 188-216.	1.6	49

#	Article	IF	Citations
127	Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clinical Chemistry, 2001, 47, 624-30.	3.2	250
128	Increased gelatinase-A and gelatinase-B activities in malignantvs. benign breast tumors. International Journal of Cancer, 2000, 86, 204-207.	5.1	99
129	Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Research, 2000, 2, 252-7.	5.0	501
130	High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. International Journal of Cancer, 1999, 84, 44-48.	5.1	126
131	Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. , 1998, 83, 2521-2527.		70
132	The urokinase-type plasminogen activator system in cancer metastasis: A review. International Journal of Cancer, 1997, 72, 1-22.	5.1	1,493
133	Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer, 1988, 62, 531-533.	4.1	302